# Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

> **NCT07397611** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Kidney Cancer
- Kidney Neoplasm
- Renal Carcinoma

## Interventions

- **DRUG:** Casdatifan
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT07397611
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-09-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07397611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07397611, "Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07397611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*